Illumina Ventures
VC Fund
Foster City, United States
Illumina Ventures is an independently managed venture fund in a strategic partnership with Illumina. Illumina provides the majority of their capital and access to the expertise and vision of the world's leading genomics solutions provider.They invest primarily in early stage companies, in areas where their expertise and special relationshipwith Illumina can add value. They typically syndicate with other leading institutional and strategic investors.Focus areas include applications of genomics in life science research, healthcare, agriculture and environmental science, public safety and personal wellness.
- Total investments:
- 88
- Last investment:
- Lead investor:
- 32%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Illumina Ventures invests in
Stages Illumina Ventures invests in
Countries Illumina Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $8M–$60M
- Series B
- $10M–$220M
- Series C
- $22M–$112M
Investment Focus
Industry
- Biotechnology 44 (50%)
- Health Care 21 (24%)
- Medical 15 (17%)
- Life Science 12 (14%)
- Genetics 10 (11%)
Stage
- Series A 22 (25%)
- Series B 16 (18%)
- Series C 11 (13%)
- Seed 10 (11%)
- Funding Round 7 (8%)
Country
- United States 41 (47%)
- United Kingdom 3 (3%)
- France 2 (2%)
- Sweden 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Arnaud Autret
Principal
|
Principal | Total investments: 4 | Find email | |
Donal D. Delaney
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email | |
Judy Koh
CFO
|
CFO | Total investments: 0 | Find email | |
Nicholas Naclerio
Founding Partner
|
Founding Partner | Total investments: 15 | Find email | |
Suresh Pisharody
Entrepreneur In Residence
|
Entrepreneur In Residence | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SyntaxBio
|
SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention. | $14.4M / Series A / Jun 21, 2026 | |
Lightcast Discovery
|
Lightcast uses a microfluidic platform to make advances towards unique clinical approaches, new therapies, and innovative products.The company's mission is to push the boundaries of complex cell analysis. Using the Lightcast platform, the company is working with major pharmaceutical companies and leading academic institutes to enable them todiscover more. The Lightcast platform allows precise and highly flexible independent control of thousands of droplets. By combining droplets containing different cells, reporters or other reagents we can perform complex workflows without the need to manipulate cells by hand.Lightcast Discovery was founded in 2019 by Cameron Frayling. | $27M / Venture - Series Unknown / Apr 14, 2026 | |
CubaseBio
|
Cubase Bio is a biotechnology business that focuses on spatial biology tools. It creates solutions for 3D spatial analysis to speed up drug discovery. | $4.6M / Seed / Feb 17, 2026 | |
Precede Biosciences
|
Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition. | $63.5M / Series B / Jan 12, 2026 | |
Alamar Biosciences
|
Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Hayward, California. | $50M / Convertible Note / Jan 11, 2026 | |
DeepSeq.AI
|
DeepSeq.AI was founded in 2019, with the overall mission of decoding the relationship between protein sequences and functions by combining wet-lab, software, and AI in a continuous development loop in order to design and screen novel protein drugs more efficiently. Up to date, DeepSeq.AI has developed a unique next-generation sequencing (NGS) basedAI platform to help pharma companies design novel protein drugs with high speed and accuracy.In 2021, DeepSeq.AI started to work with one of the top-10 global biopharma on feasibility studies to accelerate their drug discovery efforts. Those collaborations were successful, and we presented one of our successful projects at the Protein Engineering Summit Boston (PEGS) in May 2023, along with a number of other top biopharma and technology companies (e.g., Pfizer, Amgen, IBM). In Nov 2023, DeepSeq.AI was funded by UC Berkeley SkyDeck Fund and Merck Digital Sciences Studio (MDSS). | Venture - Series Unknown / Jan 07, 2026 | |
|
DeepSeq.AI
|
DeepSeq.AI was founded in 2019, with the overall mission of decoding the relationship between protein sequences and functions by combining wet-lab, software, and AI in a continuous development loop in order to design and screen novel protein drugs more efficiently. Up to date, DeepSeq.AI has developed a unique next-generation sequencing (NGS) basedAI platform to help pharma companies design novel protein drugs with high speed and accuracy.In 2021, DeepSeq.AI started to work with one of the top-10 global biopharma on feasibility studies to accelerate their drug discovery efforts. Those collaborations were successful, and we presented one of our successful projects at the Protein Engineering Summit Boston (PEGS) in May 2023, along with a number of other top biopharma and technology companies (e.g., Pfizer, Amgen, IBM). In Nov 2023, DeepSeq.AI was funded by UC Berkeley SkyDeck Fund and Merck Digital Sciences Studio (MDSS). | Venture - Series Unknown / Jan 07, 2026 | |
Iambic
|
The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant, a multi-modal transformer model that predicts clinical outcomes from the earliest stages of discovery, and NeuralPLexer, the best-in-class predictor of protein and protein-ligand structures.The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multi-parameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence. | $127.8M / Nov 10, 2025 | |
|
DeepSeq.AI
|
DeepSeq.AI was founded in 2019, with the overall mission of decoding the relationship between protein sequences and functions by combining wet-lab, software, and AI in a continuous development loop in order to design and screen novel protein drugs more efficiently. Up to date, DeepSeq.AI has developed a unique next-generation sequencing (NGS) basedAI platform to help pharma companies design novel protein drugs with high speed and accuracy.In 2021, DeepSeq.AI started to work with one of the top-10 global biopharma on feasibility studies to accelerate their drug discovery efforts. Those collaborations were successful, and we presented one of our successful projects at the Protein Engineering Summit Boston (PEGS) in May 2023, along with a number of other top biopharma and technology companies (e.g., Pfizer, Amgen, IBM). In Nov 2023, DeepSeq.AI was funded by UC Berkeley SkyDeck Fund and Merck Digital Sciences Studio (MDSS). | Seed / Nov 10, 2025 | |
|
DeepSeq.AI
|
DeepSeq.AI was founded in 2019, with the overall mission of decoding the relationship between protein sequences and functions by combining wet-lab, software, and AI in a continuous development loop in order to design and screen novel protein drugs more efficiently. Up to date, DeepSeq.AI has developed a unique next-generation sequencing (NGS) basedAI platform to help pharma companies design novel protein drugs with high speed and accuracy.In 2021, DeepSeq.AI started to work with one of the top-10 global biopharma on feasibility studies to accelerate their drug discovery efforts. Those collaborations were successful, and we presented one of our successful projects at the Protein Engineering Summit Boston (PEGS) in May 2023, along with a number of other top biopharma and technology companies (e.g., Pfizer, Amgen, IBM). In Nov 2023, DeepSeq.AI was funded by UC Berkeley SkyDeck Fund and Merck Digital Sciences Studio (MDSS). | Seed / Nov 10, 2025 | |
| See all 88 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Illumina Ventures invest in?
Illumina Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 88 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Illumina Ventures's check size?
Illumina Ventures typically joins rounds of $8M–$60M at Series A, $10M–$220M at Series B and $22M–$112M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Illumina Ventures participates in.
How do I contact Illumina Ventures?
Public channels for Illumina Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Illumina Ventures?
The team at Illumina Ventures includes Arnaud Autret (Principal), Donal D. Delaney (Chief Financial Officer) and Judy Koh (CFO), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
